Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety,
pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in
sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately
30-60 patients are expected to be enrolled in the overall study.